Cancer Program

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Varda raises $251M to leverage gravity in space for drug production
  Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
  biospace · 2d ago
• Lilly, Foghorn part ways; Wave’s FDA-approved plans
  The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
  biopharma_dive · 3d ago
• AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
  The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
  biopharma_dive · 5d ago
• Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
  Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell carcinoma (BCC).
  fiercebiotech · 5d ago
• Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
  Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
  biospace · 6d ago
• Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
  The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
  biopharma_dive · 6d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 7d ago
• Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
  Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
  biopharma_dive · 9d ago
• Merck reveals study success, and possible safety worries, for eye drug hopeful
  A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
  biopharma_dive · 10d ago